In­cyte's good week con­tin­ues with an en­cour­ag­ing up­date on IDO1 star epaca­do­stat

In­cyte’s com­plete re­sponse rate for a mid-stage com­bo of its IDO1 drug epaca­do­stat with check­point leg­end Keytru­da took a hit in the lat­est da­ta up­date, but the grow­ing biotech came away with a thumbs-up from an­a­lysts who have been track­ing this tri­al care­ful­ly.

In­cyte $IN­CY is steadi­ly beef­ing up the num­bers on their big drug. Go­ing in­to ES­MO next week — where they will add a few more re­sults — re­searchers re­port­ed on 54 pa­tients evalu­able for ef­fi­ca­cy.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER